Dehydroabietic acid

Other Names

(1R,4aS)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenecarboxylic acid(1R,4aS,10aR)-1,4a-dimethyl-7-(propan-2-yl)-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid(1R,4aS,10aR)-7-Isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid1,2,3,4,4a,9,10,10a-Octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenecarboxylic acid1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R,4aS,10aR)-1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, [1R-(1α,4aβ,10aα)]-13-Isopropylpodocarpa-8,11,13-trien-15-oic acidAbieta-8(14),9(11),12-trien-18-oic acidAbieta-8,11,13-trien-18-oic acidAbietic acid, dehydro-Acide abiéta-8(14),9(11),12-trién-18-oïqueDAADehydro-abietic acidDehydroabietateDehydroabietinsäureDHAEINECS 217-102-8NSC 2952Podocarpa-8,11,13-trien-15-oic acid, 13-isopropyl-[1R-(1alpha,4abeta,10aalpha)]-1,2,3,4,4a,9,10,10a-octahydro-7-isopropyl-1,4a-dimethylphenanthren-1-carboxylic acid

Synopsis

Dehydroabietic Acid: A Comprehensive Reference

1. Identity

Chemical and Botanical Names

Dehydroabietic acid (DHA) is a naturally occurring abietane-type diterpenoid resin acid found predominantly in coniferous trees. By ChEBI nomenclature, dehydroabietic acid is an abietane diterpenoid that is abieta-8,11,13-triene substituted at position 18 by a carboxy group. The compound is known by several synonyms, including dehydrorosin acid, and carries the IUPAC systematic name (1R,4aS,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid. In the research literature it is frequently abbreviated as DHA or DAA. It has a role as a metabolite and an allergen.

Molecular Identity

Dehydroabietic acid has the molecular formula C₂₀H₂₈O₂ and a molecular weight of 300.4 g/mol, featuring a tricyclic phenanthrene-based structure derived from abieta-8,11,13-triene substituted at the C-18 position with a carboxylic acid group. Its CAS registry number is 1740-19-8. In each molecule there are three six-membered rings, which form planar, half-chair, and chair conformations. The tricyclo-phenanthrene structure exhibits the same conformation with dehydroabietic N-methyl anilide, and the two cyclohexane rings form a trans ring junction with two methyl groups in the same side of the tricyclophenanthrene structure.

In its pure isolated form, dehydroabietic acid is a white solid or colorless needle crystal; it is slightly soluble in water but soluble in methanol, ethanol, DMSO, and other organic solvents.

Natural Sources

Dehydroabietic acid occurs naturally in the oleoresin of various coniferous trees, particularly species of the genus Pinus such as Pinus densiflora and Pinus pinea, and constitutes a major component of rosin acids extracted from pine stumps and tall oil, industrial byproducts of the kraft pulping process. Coniferous species documented to contain dehydroabietic acid include Pinus densiflora, P. sylvestris, and grand fir (Abies grandis). Along with abietic acid, dehydroabietic acid is a major compound of rosin derived from coniferous plants such as Pinus, Picea, Larix, and Abies.

In plants, it functions as a secondary metabolite involved in defense mechanisms, and it is emitted as a marker compound during the burning of conifer wood. The diterpenoids dehydroabietic and abietic acids are defense metabolites abundant in resin, and are used as biomarkers for conifer plants.

DHA forms naturally through the dehydrogenation of other resin acids, particularly abietic acid, a process occurring during resin aging or heating. Beyond its natural presence, dehydroabietic acid is also a byproduct in effluent from pulp and paper mills.

Occurrence in Rosin and Related Industrial Materials

Rosin is roughly 90% resin acids, with abietic acid being the most well-known component. In some pine species, abietic acid makes up around 15 to 16% of the total rosin by weight, while related compounds like dehydroabietic acid, palustric acid, and several pimaric-type acids fill out the rest. Data from Portuguese maritime pine (Pinus pinaster) confirm that the major constituents of its rosin are abietic acid and dehydroabietic acid.

In tall oil rosin (TOR), a mixture of eight closely related rosin acids is present, including abietic, neoabietic, palustric, levopimaric, dehydroabietic, pimaric, sandaracopimaric, and isopimaric acid.

Common Forms and Preparations

Dehydroabietic acid can be easily obtained from Pinus resin or commercial disproportionated rosin. The title compound has been isolated from disproportionated rosin, which is obtained by isomerizing gum rosin with a Pd-C catalyst. Rosin itself is a resin component collected from pine-tree gum and is typically classified into three types: gum rosin, tall rosin, and wood rosin, according to the method of collection. In research and analytical contexts, dehydroabietic acid is available as a high-purity (≥95–99%) white crystalline powder for laboratory use. The tricyclic hydrophenanthrene structure of dehydroabietic acid has strong hydrophobicity, and it can be used as raw material for the synthesis of surfactants, as well as a starting material for the design and synthesis of biological compounds.

2. Traditional and Historical Use

Rosin, the natural resin from which dehydroabietic acid is a principal constituent, has a long history of use in traditional folk medicine for treating abscesses, wounds, carbuncles, and burns. It has been employed in ancient Egypt, China, Nordic countries, and Turkey as a therapeutic remedy.

Rosins and turpentines present in pine resins have been widely used both industrially (coatings, electronics, and paint) and pharmaceutically (ointments). Rosin's oldest large-scale use was in shipbuilding. Along with tar, pitch, and turpentine, it belonged to a category called "naval stores," products derived from pine trees that kept wooden ships seaworthy.

Dehydroabietic acid is a diterpene resin acid that has been traditionally used as herbal medicine. Although dehydroabietic acid was not isolated and characterized as a distinct molecule until the modern era, the oleoresin preparations that served as traditional medicines in cultures ranging from ancient Egypt to East Asia contained significant quantities of this compound as part of the resin acid fraction. Traditional preparations of pine resin were applied topically as poultices or ointments for wound care and skin conditions, or consumed in small amounts as part of herbal formulas in Chinese traditional medicine. DAA, a naturally occurring diterpene resin acid, is contained in many dietary and herbal plants.

3. Key Constituents and Established Mechanisms of Action

The Compound as the Active Constituent

Dehydroabietic acid is itself the primary bioactive constituent of interest rather than a crude extract containing multiple components. It is a natural tricyclic diterpenic resin acid that can be readily isolated from pine rosin or disproportionate rosin, and early studies demonstrated that DHA and its derivatives possess a broad spectrum of physiological or pharmacological activities, including antimicrobial, antifungal, antiviral, anti-aging, anti-inflammatory, BK channel-opening, and herbicidal activities.

Anti-Inflammatory Mechanisms: NF-κB and AP-1 Pathways

Dehydroabietic acid clearly reduces nitric oxide (NO) production and decreases inflammatory gene expression. It displays anti-inflammatory activity at the transcriptional level in results from NF-κB- or AP-1-mediated luciferase assays. Specifically, dehydroabietic acid suppresses the activity of proto-oncogene tyrosine protein kinase (Src) and spleen tyrosine kinase (Syk) in the NF-κB cascade, and transforming growth factor beta-activated kinase 1 (TAK1) in the AP-1 cascade. Using overexpression strategies, investigators confirmed that DAA targets these kinases.

SIRT1 Activation (Sirtuin Pathway)

DAA has lifespan extension effects in Caenorhabditis elegans, prevents lipofuscin accumulation, and prevents collagen secretion in human dermal fibroblasts; these anti-aging effects are primarily mediated by SIRT1 activation. Lifespan extension effects by DAA were ameliorated in sir-2.1 mutants, and SIRT1 protein expression was increased, resulting in the deacetylation of SIRT1 target protein PGC-1α. Moreover, DAA binds directly to the SIRT1 protein independent of the SIRT1 substrate NAD⁺ levels.

PPAR-α/γ Dual Agonism (Metabolic Pathway)

Research found that DA (dehydroabietic acid) formed stable hydrogen bonds with the ligand-binding domains of PPAR-γ and PPAR-α. DA treatment also promoted 3T3-L1 differentiation via PPAR-γ activation, and mitochondrial oxygen consumption in HL7702 cells via PPAR-α activation. This dual PPAR agonism represents a potential mechanism through which dehydroabietic acid may improve insulin resistance and hepatic steatosis.

BK Channel Activation (Neurological/Cardiovascular Pathway)

DAA is a chemical modulator that opens large-conductance calcium-activated BK channels. Together, these reports suggest that DAA could be a possible treatment for acute stroke and epilepsy.

Anticancer Mechanisms: Apoptosis and Cell Cycle Arrest

DAA-regulated genes were screened using RNA-Seq and differentially expressed genes (DEGs) analysis in AGS (gastric cancer) cells. RNA-Seq analysis revealed that the expression of survivin, an apoptosis inhibitor, was significantly reduced by DAA treatment, which was confirmed by RT-PCR and Western blotting analysis. DAA also caused an increase in cleaved caspase-3, an apoptosis-activating protein.

Gastroprotective Mechanisms

The gastroprotective agent ecabet sodium (12-sulfodehydroabietic acid monosodium salt) increases the formation of prostaglandin E2 and I2 by gastric mucosa. Proposed mechanisms of action for ecabet sodium include improved blood flow in the gastric mucosa, increased gastric mucin, increased gastric mucosal PGE2, and decreased activity of pepsin. Studies on the effects of ecabet sodium on gastric mucin biosynthesis showed that intragastric administration of ecabet significantly increased glucosamine incorporation into antral mucin as well as into corpus mucin during organ culture.

4. Scientific Evidence by Area of Use

4.1 Anti-Inflammatory Activity

Type of evidence: In vitro (cell-based), no human clinical trials on dehydroabietic acid itself for inflammation.

Dehydroabietic acid (DAA) is a naturally occurring diterpene resin acid derived from coniferous plants such as Pinus and Picea. Various bioactive effects of DAA have been studied including antibacterial, antifungal, and anticancer activities; however, the anti-inflammatory mechanism of DAA remains unclear. Investigators evaluated the anti-inflammatory effect of DAA in macrophage cell lines. Dehydroabietic acid clearly reduced nitric oxide (NO) production and inflammatory gene expression, and displayed anti-inflammatory activity at the transcriptional level in results from NF-κB- or AP-1-mediated luciferase assays.

Evidence strength: Preliminary; all data are from macrophage cell lines (in vitro). No human or animal intervention studies have been reported specifically for DAA as an anti-inflammatory agent. The molecular targets (Src, Syk, TAK1) have been identified, but translation to clinical use has not been demonstrated.

4.2 Anti-Aging and Longevity Effects

Type of evidence: In vivo (model organism) and in vitro (human cell culture), no human clinical trials.

DAA has lifespan extension effects in C. elegans, prevents lipofuscin accumulation, and prevents collagen secretion in human dermal fibroblasts. These anti-aging effects are primarily mediated by SIRT1 activation. Lifespan extension effects by DAA were ameliorated in sir-2.1 mutants, and SIRT1 protein expression was increased, resulting in the deacetylation of SIRT1 target protein PGC-1α. Moreover, DAA binds directly to the SIRT1 protein independent of the SIRT1 substrate NAD⁺ levels.

Dehydroabietic acid prevents age-related pigment, lipofuscin accumulation in human dermal fibroblasts. The research identified DAA from oriental medicinal plants specifically as a SIRT1-activating compound, distinguishing it from earlier known STAC (sirtuin-activating compound) resveratrol.

Evidence strength: Preliminary. Lifespan studies are in C. elegans (nematode), a simple invertebrate model organism. In vitro studies in human dermal fibroblasts support a cellular anti-aging effect, but no animal model (mammalian) or human clinical trial data exist. Extrapolation to human longevity or anti-aging benefit is not scientifically supported at this stage.

4.3 Metabolic Effects: Diabetes and Hyperlipidemia

Type of evidence: Animal model (genetically obese mice), in vitro molecular studies, no human clinical trials.

The effects of dehydroabietic acid (DAA), a diterpene, on glucose and lipid metabolism were examined using obese diabetic KK-Ay mice. DAA treatment decreased not only plasma glucose and insulin levels but also plasma triglyceride (TG) and hepatic TG levels. DAA treatment suppressed the production of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α; proinflammatory cytokines) and increased adiponectin (an anti-inflammatory cytokine). As a result of these changes in inflammatory cytokines, accumulation of macrophages in adipose tissues was reduced.

In a further molecular mechanistic study, DA was found to form stable hydrogen bonds with the ligand-binding domains of PPAR-γ and PPAR-α. DA treatment promoted 3T3-L1 differentiation via PPAR-γ activation, and mitochondrial oxygen consumption in HL7702 cells via PPAR-α activation.

Evidence strength: Preliminary; evidence is limited to a single animal model (KK-Ay mice) and in vitro molecular docking and cell studies. No human clinical trial has investigated dehydroabietic acid for diabetes or hyperlipidemia. The mechanism of PPAR dual-agonism is mechanistically plausible but unconfirmed in humans.

4.4 Anticancer Activity

Type of evidence: In vitro (human cancer cell lines), no clinical trials.

Gastric Cancer: Previous studies demonstrated that DAA inhibits gastric cancer cell proliferation by inducing apoptosis. In one study, DAA-regulated genes were screened using RNA-Seq and differentially expressed genes (DEGs) analysis in AGS cells, revealing that the expression of survivin, an apoptosis inhibitor, was significantly reduced by DAA treatment. DAA exhibited a better inhibitory effect than the known survivin inhibitor YM-155. In these experiments, AGS cells were treated with 85 µM of DAA for 48 hours.

Derivative-Based Studies: DHAA and its derivatives have been demonstrated to possess various anticancer activities in many human cancer cell lines, and they were proved to act at various stages of tumor development to inhibit tumor initiation and promotion, as well as to induce tumor cell differentiation and apoptosis. A derivative (QC4) inhibited cell proliferation dose- and time-dependently and destroyed cell membrane integrity, activated calpain-1 autolysis, and induced apoptotic protein cleavage in gastric cancer cells.

Evidence strength: Preliminary; confined entirely to in vitro cell line experiments. Concentrations used in cell culture experiments (e.g., 85 µM) may not reflect physiologically achievable concentrations in vivo. No animal tumor models or human clinical trial data exist for dehydroabietic acid as an anticancer agent. The compound and its derivatives are currently of interest as lead structures in medicinal chemistry.

4.5 Gastroprotective Activity (Ecabet Sodium)

Type of evidence: Human clinical trials, animal studies. Note: the clinical evidence pertains specifically to ecabet sodium (12-sulfodehydroabietic acid monosodium salt), a pharmaceutical derivative of dehydroabietic acid, not to the parent compound itself.

Ecabet sodium (ES) is a 12-sulfodehydroabietic acid monosodium salt, a novel non-systemic anti-ulcer agent that belongs to the category of gastroprotective agents. The utility of ES in clinical settings has been demonstrated in various clinical trials for patients with peptic ulcer, ulcerative proctosigmoiditis, and H. pylori infection.

A prospective, double-blinded, randomized, multi-center controlled trial evaluated ecabet sodium for functional dyspepsia: investigators performed a multi-center, prospective, randomized, double-blinded controlled trial comparing ecabet sodium and cimetidine in patients with functional dyspepsia. Two hundred and seventy-two patients with dyspeptic symptoms fulfilling the Rome-II criteria were enrolled from 7 centers. In the study group (115 patients), 1.5 g ecabet sodium was given twice a day; in the control group (121 patients), 400 mg cimetidine was given twice a day. Symptoms and quality of life were analyzed at baseline, 3, 14, and 28 days after initiating treatment. Two hundred and thirty-six patients completed the trial. After 4 weeks of treatment, the rates of improvement in patients with dyspeptic symptoms were not different between the two groups (77.4% in the ecabet group and 79.3% in the cimetidine group, P > 0.05).

It was reported that ES increases the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin. In patients with gastric ulcer treated with cimetidine, additional use of ES significantly accelerates rates of ulcer healing and symptomatic relief.

The antiulcer drug ecabet 2Na (12-sulfodehydroabietic acid disodium salt) exhibits a gastroprotective activity, mainly through a local action, involving endogenous prostaglandins (PGs) and nitric oxide (NO).

Evidence strength: Moderate for ecabet sodium (the pharmaceutical derivative). Multiple human clinical trials support its use for peptic ulcer and functional dyspepsia, and it is approved as a pharmaceutical agent in Japan. However, these findings cannot be directly extrapolated to unmodified dehydroabietic acid used as a dietary supplement, as the sulfonate modification significantly alters the compound's pharmacological profile and bioavailability.

4.6 Antimicrobial and Antifungal Activity

Type of evidence: In vitro (microbial assays), some in vivo plant/agricultural models, no human clinical trials.

DHA inhibited the mycelial growth of Alternaria alternata, Botrytis cinerea, Valsa mali, Pestalotiopsis neglecta, and Fusarium oxysporum in a concentration-dependent manner, and can also inhibit the spore germination of A. alternata. DHA has bacteriostatic activity against Gram-positive and Gram-negative bacteria. The inhibitory effect on bacteria may be due to the biofilm-targeted nature of DHA, which inhibits bacterial proliferation and therefore also acts as a natural bacterial biofilm inhibitor.

Compared with control groups, the growth of A. alternata mycelium in DHA-treated groups was significantly inhibited (p < 0.05), growing slowly with color changes, and the inhibitory effect gradually increased with increasing DHA concentration. DHA could significantly inhibit spore germination in a concentration-dependent manner, with inhibition rates of 44.49% and 70.55% at EC30 and EC50 concentrations.

Evidence strength: Preliminary. Antimicrobial data are from in vitro or agricultural in vivo settings. No controlled human studies on antimicrobial applications of dehydroabietic acid have been conducted.

4.7 Cardiovascular Effects

Type of evidence: In vitro (isolated vessel preparations), animal pharmacology, no human clinical trials.

Using dehydroabietic acid as a lead compound for structural modification, 25 DAA derivatives were synthesized. Among them, compound D1 showed the strongest relaxation effect on the aortic vascular ring in vitro (Emax = 99.5 ± 2.1%, EC50 = 3.03 ± 0.96 µM), and also significantly reduced systolic and diastolic blood pressure in rats at a dose of 2.0 mg/kg in vivo. The vascular protective effect of D1 was further investigated in HUVECs. D1 induced endothelium-dependent diastole in the rat thoracic aorta in a concentration-dependent manner.

Evidence strength: Preliminary. The vasodilatory data are from synthetic derivatives of dehydroabietic acid, not the parent compound itself, and are limited to animal pharmacology and isolated tissue preparations. No human cardiovascular trials exist.

5. Body Systems and Health Areas Associated with Dehydroabietic Acid

Gastrointestinal system: Gastroprotective activity, mucus-enhancing properties, anti-ulcer effects (particularly through the ecabet sodium derivative in pharmaceutical contexts).
Metabolic and endocrine system: Potential as a dual-PPAR-α/γ agonist with dual potentials to improve insulin resistance and hepatic steatosis associated with obesity.
Immune and inflammatory system: Demonstrated anti-inflammatory effects and identified molecular mechanisms via Src, Syk, and TAK1 kinase suppression, suggesting potential as a drug or supplement to ameliorate inflammation.
Oncology (preclinical): DAA is a potential anticancer agent for gastric cancer that inhibits survivin expression. Broader cell line-based evidence exists for other cancers through its derivatives.
Aging and skin: Dehydroabietic acid prevents age-related pigment, lipofuscin accumulation in human dermal fibroblasts.
Nervous system/cardiovascular: DAA is a chemical modulator that opens large-conductance calcium-activated BK channels.
Antimicrobial: Activity against both bacteria and fungi, with evidence of biofilm inhibition in vitro.

6. Dosage Forms and Dosages Reported in Studies

Dehydroabietic acid is not currently approved or marketed as a standalone dietary supplement with established dosing guidelines. Dosages described below are exclusively those reported in specific research studies.

Animal metabolic study (KK-Ay mice, oral supplementation in chow): In genetically obese diabetic KK-Ay mice, DA supplement in the chow has been shown to effectively reduce fasting blood glucose levels. The exact dietary concentration was not specified in the available abstract data.
Vasodilatory animal study (derivatives, rat, in vivo): Compound D1, a DAA derivative, significantly reduced systolic and diastolic blood pressure in rats at a dose of 2.0 mg/kg in vivo.
Gastric cancer cell study (in vitro): AGS cells were treated with 85 µM of DAA and 5 nM of YM-155 for 48 hours for comparison of survivin inhibition.
Ecabet sodium clinical trial (human, functional dyspepsia): In the ecabet sodium study group (the pharmaceutical derivative of DAA), 1.5 g ecabet sodium was given twice a day.
Ecabet sodium mucin study (rat, intragastric): In rat antrum treated with 100 mg/kg ecabet, immunoreactivity with three distinct anti-mucin monoclonal antibodies was found in specific mucus-producing cells as well as in the secreted mucus at the surface gel layer.

No standardized human supplemental dosage for dehydroabietic acid (the parent compound) has been established or validated in clinical trials.

7. Safety Considerations and Interactions

Allergic Contact Dermatitis and Rosin Sensitization

Abietic acid itself is not allergenic; however, a number of compounds formed by air oxidation of abietic acid are potent contact allergens. Potentially allergenic oxidation products include hydroperoxides, peroxides, epoxides, and ketones of abietic acid and dehydroabietic acid. Because allergenicity is mainly due to auto-oxidation, allergenic potential is markedly affected by handling and storage times.

7-Oxodehydroabietic acid and 15-hydroxydehydroabietic acid were isolated as their methyl esters from Portuguese colophony and identified as contact allergens. Another oxidation product, 15-hydroxy-7-oxodehydroabietic acid, was also identified as a component of Portuguese gum rosin. 7-Oxodehydroabietic acid was found to be a grade III allergen according to the GPMT method. Guinea pigs induced with gum rosin showed only a low response to the isolated compounds, while patients with a known allergy to gum rosin reacted to a greater extent.

A peroxide of dehydroabietic acid was isolated from rosin using flash chromatography and preparative HPLC and identified by NMR and MS. In animal experiments, this peroxide cross-reacted with a previously identified allergen in rosin, 15-hydroperoxyabietic acid (15-HPA), despite differences in molecular weight and unsaturation. Both substances are able to react via a radical mechanism generating structurally similar molecules. In patch testing of patients, no reactions were observed to the peroxide; low skin penetration of the peroxide could be the explanation. The peroxide was considered of little clinical importance.

Contact dermatitis has occurred as a result of dehydroabietic acid in an over-the-counter hydrocolloid dressing. Chemical species consistent with the composition of disproportionated rosin (dehydroabietic acid, didehydroabietic acid, and other pimaric or isopimaric species) were identified in dichloromethane extracts of neoprene gloves, highlighting exposure pathways beyond natural botanical sources.

Occupational and Environmental Exposure

Dehydroabietic acid is also a byproduct in effluent from pulp and paper mills. During the pulping process, DHA and other resin acids are released from wood fibers into wastewater streams, raising environmental concerns.

General Toxicity Profile

According to the literature, DHA is an important natural tricyclic diterpene resin acid that is stable, has strong antioxidant capacity, good biocompatibility, and biodegradability. Nonetheless, dehydroabietic acid should be handled with care, as it is harmful if swallowed in large quantities and can cause skin and eye irritation. Formal human toxicological studies (e.g., establishing a no-observed-adverse-effect level (NOAEL), acceptable daily intake, or maximum safe human dose) have not been published for dehydroabietic acid as a dietary supplement.

Absence of Clinical Safety Data

The translational development of these resin acid compounds is hindered by the lack of clinical evidence, incomplete understanding of molecular mechanisms, and insufficient evaluation of synthetic analogs developed to improve pharmacokinetics and target engagement. Addressing these gaps will require an interdisciplinary effort that includes the integration of phytochemistry, pharmacology, and toxicology. No drug interaction studies involving dehydroabietic acid and pharmaceutical medications have been published in the peer-reviewed literature.

Summary of Evidence Status

Dehydroabietic acid is a chemically well-characterized natural diterpene resin acid with a broad range of documented in vitro and early in vivo biological activities. The totality of current scientific evidence is preliminary: the overwhelming majority of studies are cell-based (in vitro) or conducted in simple model organisms and rodents. The one area with controlled human trial data involves ecabet sodium, a synthetic sulfonated pharmaceutical derivative, not dehydroabietic acid itself. No randomized controlled clinical trials have been conducted on the parent compound as a dietary supplement in humans. Evidence for anticancer, anti-aging, anti-inflammatory, and metabolic activities, while mechanistically interesting, remains at a preclinical stage as of the available literature.

References

Health Conditions

Health conditions that Dehydroabietic acid may help support.

No conditions available.

Body Systems

Body systems that Dehydroabietic acid may help support.

No body systems available.